4 recruiting, 2 completed, 2 withdrawn. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 3, Completed 2, Withdrawn 2 |
| Phase 2 | 3 | Recruiting 2, Withdrawn 1 |
Follow Darell Bigner: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| D2C7-IT + 2141-V11 Combination Post-resection in rGBM D2C7-IT, 2141 V11 - Recurrent Glioblastoma IDH Wildtype | Phase 1 | Recruiting | Darell Bigner | 46 | 2025-03-17 | 2026-10-21 |
| Lerapolturev (PVSRIPO) in GBM Lerapolturev, Lomustine Pill - Recurrent Supratentorial Glioblastoma | Phase 2 | Recruiting | Darell Bigner | 92 | 2024-07-15 | 2026-07-20 |
| D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients D2C7-IT, 2141-V11 - Newly Diagnosed MGMT Unmethylated Glioblastoma | Phase 1 / Phase 2 | Recruiting | Darell Bigner | 50 | 2023-09-06 | 2026-10-16 |
| Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma D2C7-IT, 2141-V11 - Glioma, Malignant | Phase 1 | Recruiting | Darell Bigner | 90 | 2021-07-09 | 2026-06-04 |
| PVSRIPO in Combination With Nivolumab in Melanoma PVSRIPO, Nivolumab - Melanoma | Phase 1 | Withdrawn | Darell Bigner | 2020-06-01 | 2020-02-11 | |
| D2C7-IT With Atezolizumab for Recurrent Gliomas D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three weeks), D2C7-IT (4613.2 ng/mL via convection-enhanced delivery) - Malignant Glioma | Phase 1 | Completed | Darell Bigner | 14 | 2020-02-25 | 2026-10-14 |
| Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma PVSRIPO, Atezolizumab - Malignant Glioma | Phase 1 / Phase 2 | Withdrawn | Darell Bigner | 2020-02-01 | 2020-02-11 | |
| D2C7 for Adult Patients With Recurrent Malignant Glioma D2C7-IT - Malignant Glioma, Brain Tumor, Recurrent | Phase 1 | Completed | Darell Bigner | 81 | 2015-05-05 | 2026-06-26 |
Glioblastoma (6) · Glioma (5) · Brain Neoplasms (2) · Melanoma (1)
D2C7-(scdsFv)-PE38KDEL (5) · atezolizumab (2) · Lomustine (1) · Nivolumab (1)
United States (7)
Annick Desjardins, MD (2) · Annick Desjardins, MD, FRCPC (1) · Annick Desjardins, MD,FRCPC (1) · Daniel Landi, MD (1) · Darell D Bigner, MD, PhD (1) · Dina M Randazzo, DO (1) · Georgia Beasley (1) · Madison Shoaf, MD (1)